AbbVie Stock: The Market Is Getting It Wrong (NYSE:ABBV)

Core Viewpoint - AbbVie Inc. (ABBV) has shown strong earnings performance, particularly with its product Rinvoq, leading to a buy rating initiation in August of the previous year [1] Company Summary - AbbVie Inc. is highlighted for its robust earnings, which have been a key factor in the positive outlook for the company [1] - The focus on Rinvoq indicates a strategic emphasis on innovative therapies within AbbVie's portfolio [1] Analyst Background - The analyst has a decade of experience in investment banking, specializing in industry and company research, with a strong educational background in finance [1]